May 13, 2019
Celgene’s Pomalyst gets breakthrough therapy amrk from FDA for HIV-Positive and Negative Kaposi Sarcoma
Celgene plans additional studies with the AIDS Malignancy Consortiumin U.S. and sub-Saharan Africa
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Celgene
April 19, 2019
Worldwide Chemotherapy Drugs Market Outlook to 2023 – Featuring Pfizer, Eli Lilly, Celgene, Bristol-Myers Squibb, Merck & Co, GlaxoSmithKline, Novartis, Sanofi, and Teva Pharmaceutical Industries – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Chemotherapy Drugs Market: Analysis By Drug Type (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics), By Administration (Oral,…
March 29, 2019
Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation
NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today issued the following statement regarding Celgene’s (NASDAQ:CELG) settlement with Lotus Pharmaceutical Co., Ltd.…
March 29, 2019
Celgene Settles U.S. REVLIMID® Patent Litigation with Alvogen
Alvogen licensed to sell volume-limited amounts of generic lenalidomide in the U.S. beginning on a confidential date after the March…
March 19, 2019
Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene
Urges Shareholders to Vote “FOR” the Proposed Transaction on the WHITE Proxy Card NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY)…
February 21, 2018
Celgene gets clearance for $9Billion Juno acquisition, strengthens its hematology global reach
Celgene expects the transaction for Juno Therapeutics shares, to close in the first quarter of 2018. The company has said Wednesday…
February 19, 2018
Celgene’s Otezla research showed Improvements for treating active behçet’s disease with oral ulcers
Celgene Corporation said Monday that data from the phase III Relief clinical trial of Otezla in patients with active Behçet’s…
February 15, 2018
Celgene’s Otezla better than placebo in a phase 2 test
Celgene Corporation said that a higher proportion of patients taking apremilast 30 mg twice daily (BID) achieved clinical remission versus placebo.…
February 14, 2018
Celgene in additional $5 Billion share repurchase
Celgene Corporation has authorized the repurchase of an additional $5 billion of its common stock. As the company noted, the…
January 22, 2018
Celgene Corporation to acquire Juno Therapeutics, building global leadership in cellular immunotherapy
Celgene Corporation will acquire Juno Therapeutics, it has been announced as the two companies have signed a merger agreement.